Non-insulin-dependent diabetes mellitus (NIDDM), also known as type II diabetes, is by far the most common serious metabolic disorder, with a worldwide prevalence estimated to be between 1% and 6%, and is characterized by hyperglycemia and metabolic alterations (1) (2) (3) . In its earliest stages, insulin deficiency is not detected, but a failure of the hormone to act in target tissues has been described (1) (2) (3) . Despite considerable research effort, the causes of syndromes of insulin resistance are still not understood. Recent advances in the field have shown the high complexity of the problem. Several molecular defects have been associated with insulin resistance: e.g., genetic defects in the insulin receptor (4, 5) , mutations in the gene for glucokinase (6, 7) , or mutations in the glycogen synthase gene (8) . However, these genetic alterations account for only a small number of cases of NIDDM. The primary causes of type II diabetes remain unknown in most cases.
A major factor contributing to fasting hyperglycemia in type II diabetes is excessive hepatic glucose production. Increased gluconeogenesis is responsible for the high blood glucose level in NIDDM after an overnight fast, which, in turn, causes an increased and sustained demand for insulin secretion (9) (10) (11) . In the fasted state the rate of glucose utilization equals that of hepatic glucose output. In fasting patients with impaired glucose tolerance, the high plasma insulin cannot normalize glucose clearance (1) . The cytosolic form ofphosphoenolpyruvate carboxykinase (GTP) (PEPCK; EC 4.1.1.32) is a regulatory enzyme of gluconeogenesis (12) . PEPCK has no known allosteric modifiers and its activity is regulated by the transcription rate of its gene. Cyclic AMP and glucocorticoids increase liver PEPCK gene expression, whereas insulin has the opposite effect (13) (14) (15) formaldehyde. Northern blots were hybridized to 32P-labeled cDNAs. The PEPCK probe corresponded to the 1.7-kb Sph I-Sph I fragment of the rat PEPCK cDNA (17) ; the GLUT-4 probe corresponded to the 2.47-kb EcoRI-EcoRI fragment containing the entire rat GLUT-4 cDNA (19) , and the (-actin probe corresponded to a 1.3-kb EcoRI-EcoRI fragment ofthe Abbreviations: NIDDM, non-insulin-dependent diabetes mellitus; PEPCK, phosphoenolpyruvate carboxykinase. *To whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. rabbit cDNA. These probes were labeled with [a-32P]dCTP by use of the random priming kit as described by the manufacturer (Boehringer Mannheim). Specific activity of the DNA probe thus labeled was 4109 cpm/pg of DNA. For autoradiography, blots were placed in contact with Kodak XAR-5 film. The /3-actin signal was used to correct for loading inequalities.
Preparation and Incubation of Hepatocytes. Hepatocytes were isolated between 10 and 11 a.m. from fed mice as described (20) . After removal of nonparenchymal cells and debris, hepatocytes were suspended in Dulbecco's modified Eagle's medium (DMEM) containing 0.2% albumin and 10% fetal bovine serum. Cells were plated in 10 ml of this medium on collagen-coated dishes (5.5 x 106 cells in 10 ml per 100-mm-diameter dish) and maintained at 370C under a 5% CO2 atmosphere. After 4 hr the medium was removed and cells were washed three times in DMEM without glucose. Then 10 ml of DMEM without glucose and supplemented with 20 mM pyruvate was added to the cells, which were maintained in this medium up to 24 hr. Aliquots of 100 ul of medium were taken at various times and glucose production was determined.
Insulin (17) , which contains the entire PEPCK coding sequence and 550 bp of the promoter/regulatory region. A 4.0-kb Sph I fragment of the PEPCK gene was removed (22) and replaced by the 1.7-kb Sph I fragment of the rat PEPCK cDNA (12, 22) (Fig. 1A) . Regulatory elements in the PEPCK promoter which are responsive to cAMP, glucocorticoids, and insulin (23) (24) (25) are contained in the 550-bp segment. This region also confers tissue specificity, since it is able to direct the expression of chimeric genes mainly in the liver (26) (27) (28) . In these animals the expression of the chimeric gene is regulated by diet in a similar manner to the endogenous PEPCK gene (26) (27) (28) . Two founder mice expressing the PEPCK minigene (PP1 and PP2) were obtained when the minigene was microinjected into fertilized eggs (16) . These transgenic animals carried about three intact copies ofthe PEPCK minigene when analyzed by Southern blot (Fig. 1B) . To determine phenotypic consequences of PEPCK overexpression, both founder mice were bred to produce F1 progeny. In the experiments described below, we used mice of F1 and F2 generations (2-4 months old) from the founder PP2, since they showed higher expression ofthe transgene. However, similar results were obtained Proc. Natl. Acad. Sci. USA 91 (1994) 9153 with the line PP1. Littermates were used as controls for the transgenic animals. Transgenic mice did not show any sign of stress. They were healthy and grew normally, and no significant differences were detected in body weight when they were compared with control mice. Previous studies performed in our laboratory showed that rat and mouse PEPCK mRNAs have identical size (data not shown). The concentration of the 2.8-kb PEPCK mRNA transcript in the liver was higher (7-fold) in transgenic than in control mice. This increase was noted in both fed and fasted conditions (Fig. 1C) , indicating that the expression of the PEPCK minigene was regulated in a manner similar to that of the endogenous PEPCK gene.
Effects of PEPCK Overexpression in Cultured Hepatocytes from Transgenic Mice. To determine whether the increase in PEPCK expression led to an increase in gluconeogenesis, hepatocytes in primary culture from fed control and transgenic mice were incubated for up to 24 hr in DMEM without glucose and supplemented with pyruvate as a gluconeogenic precursor. A 2.5-fold induction of glucose production from pyruvate was noted in hepatocytes from transgenic mice (Fig.  2 ). This effect indicated that hepatocytes isolated from transgenic mice had a higher basal rate of gluconeogenesis than control animals.
Effects of PEPCK Overexpression in Glucose Homeostasis. Fed transgenic mice had 1.5-fold higher blood glucose concentration than control animals (Fig. 3A) . Furthermore, transgenic mice showed a 3-fold increase in serum insulin (Fig. 3B) . When mice expressing the PEPCK minigene were starved for 24 hr, the blood glucose levels were double those noted in control mice (Fig. 3A ). An increase in glycemia during starvation is characteristic of NIDDM (1) (2) (3) . In spite of the rise of serum insulin, transgenic mice showed a 60% reduction in liver glycogen, indicating insulin resistance (1-3) (Fig. 3C) . Furthermore, in agreement with previous reports in other animal models of NIDDM (29, 30) , transgenic mice also showed a reduction in muscle GLUT-4 mRNA concentration (Fig. 3D) .
When the intraperitoneal glucose tolerance test was performed on mice starved for 24 hr, abnormally high levels of blood glucose were detected in transgenic mice. In contrast to control mice, the glucose levels reached in transgenic mice did not return to basal values 180 min after the intraperitoneal injection of glucose (Fig. 4) . This impaired response to the glucose tolerance test suggested that transgenic mice expressing the PEPCK minigene developed diabetes. DISCUSSION In this report, we show that overexpression of the PEPCK gene leads to insulin resistance and altered glucose tolerance test, which are features of NIDDM. Thus, these results indicate that an increase in PEPCK expression is sufficient to cause hepatic glucose overproduction in an animal without any other primary alteration. PEPCK catalyzes the first step ofgluconeogenesis and the sole increase in this enzyme alone is sufficient to induce the metabolic pathway and finally to cause insulin resistance. There are other regulated steps (e.g., fructose-1,6-bisphosphatase, pyruvate kinase, transaminases) in addition to PEPCK which affect gluconeogenesis. However, since activation of PEPCK alone increases hepatic glucose output, it must have been a limiting step before activation. While defects in the enzymatic steps involved in glycolysis are now firmly linked to diabetese.g., glucokinase (maturity-onset diabetes of youth) (4, 7)-it is not established whether defects in the regulation of hepatic gluconeogenic enzymes might also cause diabetes. Medical Sciences: Valera et al.
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The primary cause(s) of NIDDM in most patients remains unknown. This study provides an animal model that suggests a general cause leading to insulin resistance. Transgenic mice overexpressing a PEPCK minigene in the liver share some of the main characteristics of NIDDM patients (1) (2) (3) , and these results indicate that the liver might be involved in the development of this pathology. Therefore, if these findings can be extrapolated to humans, the sequence of events in the development of the disease in NIDDM patients would be as follows: (i) continued high blood glucose levels, which could stem from a variety of sources-e.g., as a consequence of a primary increase in PEPCK activity; (ii) to prevent hyperglycemia, (3 cells secrete more insulin; and (iii) diabetes mellitus eventually develops in individuals whose 13 cells do not meet the sustained increased demand for insulin.
Transgenic mice overexpressing PEPCK may provide further insight into the mechanism(s) by which primary hyperglycemia (in an otherwise healthy animal) leads to insulin resistance and diabetes. Furthermore, the transgenic model presented in this study might also be used in the development of new therapies, other than insulin treatment, for diabetes. It has been observed that the expression of PEPCK is increased in patients with type II diabetes, which leads to abnormally high hepatic glucose production (9-11). Therefore, specific inhibitors of either PEPCK gene expression or PEPCK activity might decrease hepatic glucose overproduction and substantially decrease glycemia in these patients.
